Engineered miniature kidneys come of age

Method for growing kidney organoids under flow enhances their vascularization and maturation, increasing their potential for drug testing and regenerative medicine

IMAGE

Credit: Wyss Institute at Harvard University


(BOSTON and CAMBRIDGE) — In recent years, researchers have created mini-organs known as organoids in the culture dish that contain many of the cell types and complex microarchitectures found in human organs, such as the kidney, liver, intestine, and even the brain. However, most organoids grown in vitro lack the vasculature required to provide oxygen and nutrients, remove metabolic waste, and facilitate communication between different cell types that drives their maturation into truly functional tissue building blocks.

For kidney organoids, this shortcoming prevents researchers from emulating key kidney functions in vitro, including blood filtration, reabsorption, and urine production. Creating robustly vascularized kidney organoids could enable better modeling of kidney diseases, enhance renal drug toxicity testing and, ultimately, lead to new building blocks for renal replacement therapies.

Now, a research team at the Wyss Institute for Biologically Inspired Engineering, the Harvard Paulson School of Engineering and Applied Sciences (SEAS), Brigham and Women’s Hospital, and the Harvard Stem Cell Institute led by Jennifer Lewis and Ryuji Morizane has developed a powerful new approach as part of the Institute’s new 3D Organ Engineering Initiative. By exposing stem cell-derived organoids to fluidic shear stress, they were able to significantly expand organoid-derived vascular networks, and improve the maturation of kidney compartments in comparison to previous static culture methods. The work is published in Nature Methods.

In 2015, Ryuji Morizane and Joseph Bonventre developed a method that enabled them to derive 3D kidney organoids from human pluripotent stem cells. “While our organoids and those generated in other laboratories contained large numbers of well-organized nephrons and primitive blood vessels, they still lacked pervasive vascular compartments with perfusable lumens,” said co-corresponding author Morizane, M.D., Ph.D., Assistant Professor at Brigham and Women’s Hospital and Harvard Medical School (HMS), and a member of the Harvard Stem Cell Institute.

More recently, researchers around the world have matured kidney organoids by implanting them into animals where they can connect to the host’s vasculature in vivo. “For the first time, our study demonstrates that by exposing growing organoids to fluid flow, a mechanical cue known to play an important role for tissue development in the body, we can greatly enhance their vascularization and maturation in vitro,” said Morizane.

To accomplish this feat, the team used expertise from the Lewis lab that has pioneered strategies to create vascularized human tissues, including 3D kidney-on-chip models, using 3D bioprinting that can be perfused and sustained for long durations. Based on these findings, they hypothesized that fluid flow could also promote the formation of blood vessels from precursor endothelial cells found in growing kidney organoids.

“We determined the right combination of underlying extracellular matrix, media additives, and fluidic shear stress under which human stem-cell derived organoids would flourish when grown in our 3D-printed millifluidic chips,” said Kimberly Homan, Ph.D., who with Navin Gupta, M.D., is a first author on the study. Gupta added that “the vascular networks form close to the epithelial structures that build the glomerular and tubular compartments, and in turn promote epithelial maturation. This integrated process works really like a two-way street.” Homan is a Research Associate in Lewis’ group at the Wyss Institute and SEAS, and Gupta is a Clinical Research Fellow working on Morizane’s team at the Brigham.

The vessels growing on the 3D-printed chips form an interconnected network with open lumens, which can be perfused with fluids as confirmed by directly imaging fluorescent beads moving freely through them. “We were excited to see that these vascularized glomerular and tubular structures develop through some of the same stages that nephrons experience during normal kidney development in vivo,” said Homan.

“This important advance opens up new avenues for accurately testing drug toxicity in vitro in differentiated nephron compartments and modeling kidney diseases, like polycystic kidney disease, that affect specific structures and cell types using patient-derived stem cells as the starting point,” said co-corresponding author Lewis, Sc.D., who is a Core Faculty member of the Wyss Institute and co-leader of its 3D Organ Engineering Initiative. “Our method may pave the way to also vascularize other types of organoids, such as the liver organoids.” Lewis is also the Hansjörg Wyss Professor of Biologically Inspired Engineering at SEAS and a member of the Harvard Stem Cell Institute.

“This study is a great example of the importance of mechanobiology and the potential power of the Wyss Institute’s 3D Organ Engineering Initiative. It provides an important cornerstone for many efforts that aim to create functional human tissues de novo for research, pharmaceutical and tissue regenerative applications,” said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at HMS and the Vascular Biology Program at Boston Children’s Hospital, as well as Professor of Bioengineering at SEAS.

###

Other authors on the study are Joseph Bonventre, M.D., Ph.D., the Samuel A. Levine Professor of Medicine at HMS, Chief of the Division of Renal Medicine at the Brigham, and member of the Harvard Stem Cell Institute; past and present members of Lewis’ team, including Katharina Kroll, Mark Skylar-Scott, Ph.D., David Kolesky, Ph.D., Donald Mau, and Thomas Ferrante; Tomoya Miyoshi on Morizane’s team; and M. Todd Valerius, Ph.D., Principle Investigator at the Brigham. The study was funded by the National Institutes of Health, Harvard’s Wyss Institute for Biologically Inspired Engineering, and the Harvard Stem Cell Institute.

PRESS CONTACT

Wyss Institute for Biologically Inspired Engineering at Harvard University

Benjamin Boettner, [email protected], +1 617-432-8232

Brigham and Women’s Hospital

Haley Bridger, [email protected], +1 617-525-6383

MULTIMEDIA AVAILABLE

The Wyss Institute for Biologically Inspired Engineering at Harvard University uses Nature’s design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world. Wyss researchers are developing innovative new engineering solutions for healthcare, energy, architecture, robotics, and manufacturing that are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances, and formation of new startups. The Wyss Institute creates transformative technological breakthroughs by engaging in high risk research, and crosses disciplinary and institutional barriers, working as an alliance that includes Harvard’s Schools of Medicine, Engineering, Arts & Sciences and Design, and in partnership with Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Boston Children’s Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, Boston University, Tufts University, Charité – Universitätsmedizin Berlin, University of Zurich and Massachusetts Institute of Technology.

The Harvard John A. Paulson School of Engineering and Applied Sciences serves as the connector and integrator of Harvard’s teaching and research efforts in engineering, applied sciences, and technology. Through collaboration with researchers from all parts of Harvard, other universities, and corporate and foundational partners, we bring discovery and innovation directly to bear on improving human life and society.

Brigham and Women’s Hospital

Brigham Health, a global leader in creating a healthier world, consists of Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, the Brigham and Women’s Physicians Organization and many related facilities and programs. With more than 1,000 inpatient beds, approximately 60,000 inpatient stays and 1.7 million outpatient encounters annually, Brigham Health’s 1,200 physicians provide expert care in virtually every medical and surgical specialty to patients locally, regionally and around the world. An international leader in basic, clinical and translational research, Brigham Health has nearly 5,000 scientists, including physician-investigators, renowned biomedical researchers and faculty supported by over $700 million in funding. The Brigham’s medical preeminence dates back to 1832, and now, with 19,000 employees, that rich history is the foundation for its commitment to research, innovation, and community. Boston-based Brigham and Women’s Hospital is a teaching affiliate of Harvard Medical School and dedicated to educating and training the next generation of health care professionals. For more information, resources, and to follow us on social media, please visit brighamandwomens.org.

Media Contact
Benjamin Boettner
[email protected]
917-913-8051

Related Journal Article

http://dx.doi.org/10.1038/s41592-019-0325-y

Comments